SLC2A5 and pancreatic ductal adenocarcinoma: To test directly if deletion of the SLC2A5 gene impacts cancer progression and migration, we used CRISPR/Cas9 gene editing to inactivate the SLC2A5 gene in a highly metastatic pancreatic ductal adenocarcinoma MIA-PaCa-2 cell line, and fibrosarcoma HT1080tdT cells (Figure 1A).